Trastuzumab improves long-term outcomes in obese patients with HER2-positive breast c
 

A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients.

More...